Biocompatibility of new peritoneal dialysis solutions: clinical experience.
The successful development of peritoneal dialysis (PD) during the last two decades has been made possible by using well-established glucose-based solutions with lactate as buffer. On the other hand, awareness has been increasing about the potentially negative effects of the high concentrations of glucose and lactate, and the low pH of conventional PD solutions. This awareness has prompted an intensive effort to search for and test alternative solutions. As a result, three new, more biocompatible solutions-containing either less glucose or less lactate--are available. Amino acid-based solution uses amino acids instead of glucose as the osmotic agent; it is indicated for treatment of malnutrition. The higher pH and absence of glucose in this solution may prevent alterations of the peritoneal membrane caused by acidity and high glucose concentrations. Bicarbonate/lactate-buffered solution contains a physiologic concentration of bicarbonate and a reduced concentration of lactate; it also has a physiologic pH and markedly reduced levels of glucose degradation products (GDPs). Icodextrin-based solution contains icodextrin as the osmotic agent; it is indicated for long dwells, delivering sustained ultrafiltration for more than 16 hours. This iso-osmolar glucose-free solution may reduce peritoneal membrane alterations caused by glucose or the hyperosmolality (or both) of conventional solutions. Clinical experience of the new solutions is now extensive, and their efficacy and safety are well documented. It therefore seems appropriate to state that we have entered a new era of PD therapy. Each of the new solutions may be less damaging to the peritoneal membrane than conventional solution. In addition, they permit better management of malnutrition and fluid status, and may thus help to improve PD patient survival. Although the effects of each of these new solutions have been well described, clinical documentation of the combined use of these new biocompatible PD solutions is still insufficient. However, the results of studies are expected, during the coming years, to support the combined use of the new solutions as the preferred standard practice for PD.
Garcia-Lopez
E
E
Department of Clinical Sciences, Karolinska Institute, Stockholm, Sweden.
Lindholm
B
B
Tranaeus
A
A
D000596:Amino Acids; D001639:Bicarbonates; D015314:Dialysis Solutions / Q000737:chemistry; D005936:Glucans; D005947:Glucose; D006801:Humans; D006863:Hydrogen-Ion Concentration; D000077607:Icodextrin; D019344:Lactic Acid; D010530:Peritoneal Dialysis; D013997:Time Factors
D000596:Amino Acids; D001639:Bicarbonates; D015314:Dialysis Solutions; D005936:Glucans; D000077607:Icodextrin; D019344:Lactic Acid; D005947:Glucose